ScienceDirect® Home Skip Main Navigation Links
You have guest access to ScienceDirect. Find out more.
 
Home
Browse
My Settings
Alerts
Help
 Quick Search
 Search tips (Opens new window)
    Clear all fields    
advertisementadvertisement
Current Opinion in Pharmacology
Volume 5, Issue 6, December 2005, Pages 583-588
Gastrointestinal/Endocrine and metabolic diseases
 
Font Size: Decrease Font Size  Increase Font Size
 Abstract - selected
Article
Purchase PDF (109 K)

 
 
 
Related Articles in ScienceDirect
View More Related Articles
 
View Record in Scopus
 
doi:10.1016/j.coph.2005.06.006    How to Cite or Link Using DOI (Opens New Window)
Copyright © 2005 Elsevier Ltd All rights reserved.

Gastrointestinal pharmacology: irritable bowel syndrome

Lionel BuenoE-mail The Corresponding Author

Neurogastroenterology Unit INRA, 180 Chemin de Tournefeuille-BP3, 31931 Toulouse, France

Available online 26 September 2005.

Purchase the full-text article



References and further reading may be available for this article. To view references and further reading you must purchase this article.

Over the past 30 years, the main treatment of irritable bowel syndrome has aimed to normalize gastrointestinal transit using either laxatives or antidiarrheal agents, with or without the concurrent use of spasmolytics. The recent introduction of serotonin-related drugs has stimulated investigations into the pathophysiology of irritable bowel syndrome, including an evaluation of visceral sensitivity. At the same time, more information has been acquired on the status of the local immune system as a possible cause for sensitization of nerve terminals. Such investigations have stimulated the emergence of new concepts and original candidate drugs for the treatment of this functional disorder. Particular attention is devoted to the correction of visceral hyperalgesia.

Article Outline

Introduction
Classical therapies for IBS
Psychotherapeutic treatments
Targeting 5-HT receptors
5-HT3 receptor antagonists
5-HT4 receptor agonists
Mixed 5-HT4 agonist and 5-HT3 antagonist
Other pharmacological approaches
Tachykinin antagonists
Opioid agonists and antagonists
Cholecystokinin-A antagonists
New identified targets
Corticotropin-releasing factor receptors
NGF and its receptors
Proteinase-activated receptor 2
Conclusions
References and recommended reading
References

Current Opinion in Pharmacology
Volume 5, Issue 6, December 2005, Pages 583-588
Gastrointestinal/Endocrine and metabolic diseases
 
Home
Browse
My Settings
Alerts
Help
Elsevier.com (Opens new window)
About ScienceDirect  |  Contact Us  |  Information for Advertisers  |  Terms & Conditions  |  Privacy Policy
Copyright © 2008 Elsevier B.V. All rights reserved. ScienceDirect® is a registered trademark of Elsevier B.V.